How Phase 2 POC opens the best-in-class floodgates for patients and investors.

How knowledge graphs that reason turn hard drug decisions into routine queries.

Why picking an AI model isn't picking a database—it's picking a portfolio, and the portfolio changes quarterly.

Why structured data with strong schemas is the moat that separates insight from noise in drug discovery.

Why the 'Valley of Death' is actually an execution gap, and how we algorithmicize the bridge.